BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res 2016;5:39-50. [PMID: 26958492 DOI: 10.3978/j.issn.2218-6751.2016.01.03] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
Number Citing Articles
1 Yu L, Lu Y, Yao Y, Liu Y, Wang Y, Lai Q, Zhang R, Li W, Wang R, Fu Y, Tao Y, Yi S, Gou L, Chen L, Yang J. Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models. Oncotarget 2018;9:5197-207. [PMID: 29435172 DOI: 10.18632/oncotarget.23708] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
2 Tsoukalas N, Aravantinou-Fatorou E, Baxevanos P, Tolia M, Tsapakidis K, Galanopoulos M, Liontos M, Kyrgias G. Advanced small cell lung cancer (SCLC): new challenges and new expectations. Ann Transl Med 2018;6:145. [PMID: 29862234 DOI: 10.21037/atm.2018.03.31] [Cited by in Crossref: 29] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
3 Friedman JR, Perry HE, Brown KC, Gao Y, Lin J, Stevenson CD, Hurley JD, Nolan NA, Akers AT, Chen YC, Denning KL, Brown LG, Dasgupta P. Capsaicin synergizes with camptothecin to induce increased apoptosis in human small cell lung cancers via the calpain pathway. Biochem Pharmacol 2017;129:54-66. [PMID: 28104436 DOI: 10.1016/j.bcp.2017.01.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
4 Güçlü E, Eroğlu Güneş C, Kurar E, Vural H. Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy. Med Oncol 2021;38:113. [PMID: 34378101 DOI: 10.1007/s12032-021-01562-2] [Reference Citation Analysis]
5 Li Q, Wu T, Jing L, Li MJ, Tian T, Ruan ZP, Liang X, Nan KJ, Liu ZY, Yao Y, Guo H. Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials. Medicine (Baltimore) 2017;96:e6412. [PMID: 28353568 DOI: 10.1097/MD.0000000000006412] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Rösner E, Kaemmerer D, Neubauer E, Sänger J, Lupp A. Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours. Endocr Connect 2021;10:180-90. [PMID: 33475525 DOI: 10.1530/EC-20-0540] [Reference Citation Analysis]
7 Mamesaya N, Wakuda K, Omae K, Miyawaki E, Kotake M, Fujiwara T, Kawamura T, Kobayashi H, Nakashima K, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Mori K, Harada H, Endo M, Nakajima T, Takahashi T. Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy. Oncotarget 2018;9:17664-74. [PMID: 29707139 DOI: 10.18632/oncotarget.24830] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
8 Chen P, Zhao L, Wang H, Zhang L, Zhang W, Zhu J, Yu J, Zhao S, Li W, Sun C, Wu C, He Y, Zhou C. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer. J Immunother Cancer 2021;9:e002554. [PMID: 34362829 DOI: 10.1136/jitc-2021-002554] [Reference Citation Analysis]
9 Hong B, Wang H, Deng K, Wang W, Dai H, Yan Lui VW, Lin W. Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer. Oncotarget 2017;8:106486-98. [PMID: 29290965 DOI: 10.18632/oncotarget.18984] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
10 Karakattu S, Yorke J, Hoskere T, Stewart L, ElMinaoui W. A rare case of multiple secondary endotracheal metastasis from early stage small cell cancer. Respir Med Case Rep 2020;30:101103. [PMID: 32528842 DOI: 10.1016/j.rmcr.2020.101103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Trinh CT, Nguyen TTT, Van HAT, Hoang VT. A Rare Case of Diffuse Subependymal Periventricular Metastases from Small Cell Lung Carcinoma. Case Rep Oncol 2020;13:1304-10. [PMID: 33250746 DOI: 10.1159/000508828] [Reference Citation Analysis]
12 Li H, Fang H, Chang L, Qiu S, Ren X, Cao L, Bian J, Wang Z, Guo Y, Lv J, Sun Z, Wang T, Li B. TC2N: A Novel Vital Oncogene or Tumor Suppressor Gene In Cancers. Front Immunol 2021;12:764749. [DOI: 10.3389/fimmu.2021.764749] [Reference Citation Analysis]
13 Wu J, Di D, Zhao C, Pan Q, Liu Y, Zhang X, Zhao X, Chen H. Clinical Significance of Gli-1 And Caveolin-1 Expression in the Human Small Cell Lung Cancer. Asian Pac J Cancer Prev 2018;19:401-6. [PMID: 29479989 DOI: 10.22034/APJCP.2018.19.2.401] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
14 Oliver DE, Donnelly OG, Grass GD, Naghavi AO, Yang GQ, Dilling TJ, Perez BA. Extracranial metastatic burden in extensive-stage small cell lung cancer: implications for prophylactic cranial irradiation. J Thorac Dis 2018;10:4321-7. [PMID: 30174879 DOI: 10.21037/jtd.2018.06.92] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Testori A, Ferraroli G, De Carlo C, Bossi P, Alloisio M, Mangiameli G. Tracheal polypoid combined small cell lung cancer (C-SCLC): A case report. Thorac Cancer 2021;12:2035-8. [PMID: 33990130 DOI: 10.1111/1759-7714.13992] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Luo H, Zhang Y, Qin G, Jiang B, Miao L. LncRNA MCM3AP-AS1 sponges miR-148a to enhance cell invasion and migration in small cell lung cancer. BMC Cancer 2021;21:820. [PMID: 34271873 DOI: 10.1186/s12885-021-08365-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Xu L, Zhang G, Song S, Zheng Z. Surgery for small cell lung cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey from 2010 to 2015. Medicine (Baltimore) 2019;98:e17214. [PMID: 31577711 DOI: 10.1097/MD.0000000000017214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Deng M, Ma X, Liang X, Zhu C, Wang M. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget 2017;8:37200-7. [PMID: 28380461 DOI: 10.18632/oncotarget.16553] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
19 Zhu Y, Wu S. [Immune Characteristics of Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:889-96. [PMID: 33070515 DOI: 10.3779/j.issn.1009-3419.2020.101.33] [Reference Citation Analysis]
20 Saito M, Saito K, Shiraishi K, Maeda D, Suzuki H, Minamiya Y, Kono K, Kohno T, Goto A. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol 2018;8:310-4. [PMID: 29435295 DOI: 10.3892/mco.2017.1536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
21 Crinò L, Delmonte A. Perspectives in small cell lung cancer: is something moving? Transl Lung Cancer Res 2017;6:S47-50. [PMID: 29299410 DOI: 10.21037/tlcr.2017.10.12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Sundaresan V, Lin VT, Liang F, Kaye FJ, Kawabata-Iwakawa R, Shiraishi K, Kohno T, Yokota J, Zhou L. Significantly mutated genes and regulatory pathways in SCLC-a meta-analysis. Cancer Genet 2017;216-217:20-8. [PMID: 29025592 DOI: 10.1016/j.cancergen.2017.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
23 Xu F, Ren X, Chen Y, Li Q, Li R, Chen Y, Xia S. Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis. BMC Cancer 2018;18:808. [PMID: 30097029 DOI: 10.1186/s12885-018-4715-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
24 Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. Br J Cancer 2017;117:8-14. [PMID: 28510571 DOI: 10.1038/bjc.2017.137] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
25 Lallo A, Gulati S, Schenk MW, Khandelwal G, Berglund UW, Pateras IS, Chester CPE, Pham TM, Kalderen C, Frese KK, Gorgoulis VG, Miller C, Blackhall F, Helleday T, Dive C. Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. Br J Pharmacol 2019;176:436-50. [PMID: 30427531 DOI: 10.1111/bph.14542] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
26 Shimojo M, Kasahara Y, Inoue M, Tsunoda SI, Shudo Y, Kurata T, Obika S. A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer. Sci Rep 2019;9:7618. [PMID: 31110284 DOI: 10.1038/s41598-019-43100-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
27 Chen Y, Yu M, Liu Z, Zhang Y, Li Q, Yang G. Effects of traditional Chinese medicine combined with chemotherapy for extensive-stage small-cell lung cancer patients on improving oncologic survival: study protocol of a multicenter, randomized, single-blind, placebo-controlled trial. Trials 2021;22:437. [PMID: 34238342 DOI: 10.1186/s13063-021-05407-1] [Reference Citation Analysis]
28 Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). J Immunother Cancer. 2019;7:65. [PMID: 30850021 DOI: 10.1186/s40425-019-0540-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 44] [Article Influence: 11.3] [Reference Citation Analysis]
29 Lee MS, Jung K, Song JY, Sung MJ, Ahn SB, Lee B, Oh DY, Choi YL. IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer. Mol Ther Oncolytics 2020;16:188-96. [PMID: 32099898 DOI: 10.1016/j.omto.2019.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V, Wang Y, Sattler M. Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. Oncotarget 2018;9:26226-42. [PMID: 29899855 DOI: 10.18632/oncotarget.25360] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
31 Xiang T, Kang X, Gong Z, Bai W, Chen C, Zhang W. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies. Cancer Chemother Pharmacol 2017;79:791-800. [PMID: 28314991 DOI: 10.1007/s00280-017-3280-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
32 Lu HY, Qin J, Han N, Lei L, Xie F, Li C. EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients. Onco Targets Ther 2018;11:2217-26. [PMID: 29720878 DOI: 10.2147/OTT.S159612] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
33 Hamilton G, Rath B. Circulating tumor cell interactions with macrophages: implications for biology and treatment. Transl Lung Cancer Res 2017;6:418-30. [PMID: 28904886 DOI: 10.21037/tlcr.2017.07.04] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
34 Tsiouda T, Sardeli C, Porpodis K, Pilikidou M, Apostolidis G, Kyrka K, Miziou A, Kyrka K, Tsingerlioti Z, Papadopoulou S, Heva A, Koulouris C, Giannakidis D, Boniou K, Kesisoglou I, Vagionas A, Kosmidis C, Sevva C, Papazisis G, Goganau AM, Sapalidis K, Tsakiridis K, Tryfon S, Platanas M, Baka S, Zaric B, Perin B, Petanidis S, Zarogoulidis P. Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer. J Cancer 2020;11:3407-15. [PMID: 32231747 DOI: 10.7150/jca.40196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Xu H, Cai T, Carmona GN, Abuhatzira L, Notkins AL. Small cell lung cancer growth is inhibited by miR-342 through its effect of the target gene IA-2. J Transl Med 2016;14:278. [PMID: 27670444 DOI: 10.1186/s12967-016-1036-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
36 Zhou F, Zhao W, Gong X, Ren S, Su C, Jiang T, Zhou C. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer. J Immunother Cancer 2020;8:e001300. [PMID: 32900864 DOI: 10.1136/jitc-2020-001300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Liu H, Xue YC, Deng H, Mohamud Y, Ng CS, Chu A, Lim CJ, Lockwood WW, Jia WWG, Luo H. MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer. Mol Ther Oncolytics 2020;16:207-18. [PMID: 32123721 DOI: 10.1016/j.omto.2020.01.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
38 Ujhazy P, Lindwasser OW. Small cell lung cancer: updates and new concepts. Transl Lung Cancer Res 2018;7:1-3. [PMID: 29535908 DOI: 10.21037/tlcr.2018.02.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
39 Lohinai Z, Megyesfalvi Z, Suda K, Harko T, Ren S, Moldvay J, Laszlo V, Rivard C, Dome B, Hirsch FR. Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases. Transl Lung Cancer Res 2019;8:938-50. [PMID: 32010572 DOI: 10.21037/tlcr.2019.11.30] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
40 Mao Y, Xue P, Li L, Xu P, Cai Y, Chu X, Jiang P, Zhu S. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA‑gene pairs in small‑cell lung cancer. Mol Med Rep 2019;20:2199-208. [PMID: 31257520 DOI: 10.3892/mmr.2019.10441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
41 Sen M, Kindsfather A, Danilova L, Zhang F, Colombo R, LaPorte MG, Kurland BF, Huryn DM, Wipf P, Herman JG. PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies. Epigenetics 2020;15:604-17. [PMID: 31595832 DOI: 10.1080/15592294.2019.1676597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Liu H, Luo H. Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges. Viruses 2021;13:1082. [PMID: 34198859 DOI: 10.3390/v13061082] [Reference Citation Analysis]
43 Klameth L, Rath B, Hochmaier M, Moser D, Redl M, Mungenast F, Gelles K, Ulsperger E, Zeillinger R, Hamilton G. Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance. Sci Rep 2017;7:5337. [PMID: 28706293 DOI: 10.1038/s41598-017-05562-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
44 Liu W, Liang F, Yang G, Xian L. LncRNA LINC01116 sponges miR-93-5p to promote cell invasion and migration in small cell lung cancer. BMC Pulm Med 2021;21:50. [PMID: 33535997 DOI: 10.1186/s12890-020-01369-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Ponath P, Menezes D, Pan C, Chen B, Oyasu M, Strachan D, LeBlanc H, Sun H, Wang XT, Rangan VS, Deshpande S, Cristea S, Park KS, Sage J, Cardarelli PM. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res 2018;24:5178-89. [PMID: 30021910 DOI: 10.1158/1078-0432.CCR-18-0018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
46 Zhu K, Jiang M, Xu Y, Chen P, Wang H, Yu J, Zhu J, Zhao W, Meng D, He Y. Curative efficacy might be an early predictor of prognosis in patients with small cell lung cancer treated with 2 cycles of platinum-based first-line chemotherapy. J Thorac Dis 2021;13:1205-14. [PMID: 33717593 DOI: 10.21037/jtd-21-216] [Reference Citation Analysis]
47 Masciale V, Grisendi G, Banchelli F, D'Amico R, Maiorana A, Morandi U, Dominici M, Aramini B. Cancer stem-neuroendocrine cells in an atypical carcinoid case report. Transl Lung Cancer Res. 2019;8:1157-1162. [PMID: 32010593 DOI: 10.21037/tlcr.2019.12.07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]